Drug Delivery Systems Using Surface Markers for Targeting Cancer Stem Cells

Curr Pharm Des. 2020;26(17):2057-2071. doi: 10.2174/1381612826666200406084900.

Abstract

The innate abilities of cancer stem cells (CSCs), such as multi-drug resistance, drug efflux, quiescence and ionizing radiation tolerance, protect them from most traditional chemotherapeutics. As a result, this small subpopulation of persistent cells leads to more aggressive and chemoresistant cancers, causing tumour relapse and metastasis. This subpopulation is differentiated from the bulk tumour population through a wide variety of surface markers expressed on the cell surface. Recent developments in nanomedicine and targeting delivery methods have given rise to new possibilities for specifically targeting these markers and preferentially eliminating CSCs. Herein, we first summarize the range of surface markers identifying CSC populations in a variety of cancers; then, we discuss recent attempts to actively target CSCs and their niches using liposomal, nanoparticle, carbon nanotube and viral formulations.

Keywords: Cancer Stem Cells (CSC); liposomes; nanoparticles; stem cell surface markers; surface markers; targeted delivery..

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Nanomedicine
  • Neoplasms* / drug therapy
  • Neoplastic Stem Cells / pathology

Substances

  • Antineoplastic Agents